Table 3.
Meta-analysis of the association between LMR and clinicopathological features of ovarian cancer
| Characteristics | No. of studies | No. of patients | OR (95% CI) | p | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (%) | Ph | |||||
| Age (≥ 60 vs. < 60) | 3 | 626 | 2.07 (1.22–3.50) | 0.007 | 42 | 0.18 |
| Gender (male vs. female) | 4 | 4818 | 1.18 (0.68–2.04) | 0.56 | 70 | 0.02 |
| Smoking status (ever/current vs. never) | 2 | 394 | 0.95 (0.63–1.45) | 0.82 | 0 | 0.80 |
| Differentiation (low vs. moderate/high) | 5 | 4886 | 1.60 (1.10–2.32) | 0.01 | 35 | 0.19 |
| Tumor size (> 3 cm vs. < 3 cm) | 2 | 496 | 1.86 (0.74–4.71) | 0.19 | 71 | 0.06 |
| T stage (III-IV vs. I-II) | 3 | 4390 | 1.13 (1.01–1.28) | 0.04 | 0 | 0.79 |
| Lymph node metastasis (yes vs. no) | 3 | 4390 | 1.22 (1.06–1.39) | 0.005 | 0 | 0.67 |
| Distant metastasis (yes vs. no) | 1 | 124 | 1.46 (0.37–5.73) | 0.59 | – | – |
| Multiplicity (multiple vs. solitary) | 2 | 496 | 1.04 (0.68–1.58) | 0.86 | 0 | 0.49 |
| Concomitant Cis (yes vs. no) | 2 | 4322 | 0.88 (0.78–0.99) | 0.03 | 0 | 0.87 |
Cis carcinoma in situ